FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer By Ogkologos - January 17, 2025 819 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ADRIATIC study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas December 21, 2022 Adjusting to the Challenges of Life After Cancer: An Expert Perspective May 5, 2022 France Bans all Textured and Polyurethane Breast Implants Amid BIA-ALCL Cancer... April 5, 2019 Vorasidenib Treatment Shows Promise for Some Low-Grade Gliomas June 27, 2023 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΠΑΧΕΩΣ ΕΝΤΕΡΟΥ NF1 Associated with More Cancer Types Than Previously Known Got the COVID Blues? For Children with Neuroblastoma, Trial Results Highlight Continued Evolution of Treatment
